NuvOx Pharma is in a Phase 1b clinical trial for its first indication - a radiation sensitizer for oncology. Most cancerous tumors are hypoxic, and this is a problem during radiation therapy because the presence of oxygen increases the effect of radiation on tissue. NuvOx’s drug NVX-108, based on a proprietary nanotechnology platform, is designed to increase the level of oxygen in hypoxic tumors in order to increase the effect of radiation on them. By doing this, the company's intention is to improve the effectiveness of radiation therapy in order to increase survival and decrease recurrence.
In addition, the company has pre-clinical data showing improved outcomes in five different life-threatening indications where tissue hypoxia plays a critical role.
- vaso-occlusive crisis in sickle cell disease
- myocardial infarction,
- traumatic brain injury
- hemorrhagic shock.
The company is seeking partners with the ability to fund further clinical trials.